Harrow (HROW) shares soared 11.4% in the last trading session to close at $34.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

Fintel reports that on July 11, 2025, Cantor Fitzgerald initiated coverage of Harrow (NasdaqGM:HROW) with a Overweight ...

We just received data on a new analyst forecast for $HROW. Steve Seedhouse from Cantor Fitzgerald set a price target of 76.0 for HROW.

Harrow (NASDAQ:HROW) stock gains as Cantor Fitzgerald gives an Overweight rating for the company, citing a conservative outlook. Read more here.

Get the latest Harrow, Inc. (HROW) stock news and headlines to help you in your trading and investing decisions.

Is HROW a good stock to buy now? Harrow Health, Inc. (NASDAQ: HROW) investors should be aware of an increase in activity from the world's largest hedge funds lately.

Harrow has successfully leveraged its compounding pharmacy to drive rapid branded drug growth. My valuation suggests substantial upside if growth continues. Read the full stock analysis.

Wasatch Global Investors, an asset management company, released its “Wasatch Micro Cap Value Strategy” fourth-quarter 2023 investor letter. A copy of the same can be downloaded here.

Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.